Mr. Tony O'Brien:

There would not be evidence that would be available to us. I am obviously aware of the speculation that relates to that. The current arrangements are based on negotiation such as the IPHA deal last year. Clearly negotiation is a two-way deal. One can only negotiate someone down to the level they are prepared to negotiate down to. That having been said, the IPHA deal at the end of last year will produce €400 million over four years that otherwise would not be available through the reduced cost of those drugs. Further legislative developments such as reference pricing, however, will produce even greater benefits for us when that comes in.